Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fluticasone propionate/salmeterol HFA MDI in infantile bronchial asthma (Japanese 6 months–4 years)
2016-003479-22Phase 4
- Sponsor
- GSK
- Start
- Nov 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised trial of salmeterol + fluticasone in asthma (2 arms), sponsored by GSK. Primary endpoint: Mean change from baseline in total asthma symptom score at end of 8-week treatment.
02
Drugs
salmeterol + fluticasone
03
Conditions
asthma
Beyond the preview
Go deeper on 2016-003479-22.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-003479-22.